Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas

Cnbc · 🇺🇸 public United States · Jun 03, 2026 · 680 words · By Angelica Peebles

Pharmaceutical Investment Strategy Market Capitalization Corporate Expansion

headphones Listen to the eFinder podcast briefing

Ready to play

Daily briefing

What to know about Pharmaceutical Investment Strategy

In addition to running Eli Lilly's oncology business, he's now responsible for finding the drugmaker's next opportunities as head of business development.

Claims checked 14

Techniques found 1

Topics 3

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center80%

Right20%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

In addition to running Eli Lilly's oncology business, he's now responsible for finding the drugmaker's next opportunities as head of business development.

Why it matters

And Lilly, now the world's largest pharmaceutical company, is hungrier than ever for deals.

Common ground

"The company's financial strength right now, driven mostly by the weight loss business, is so strong," Van Naarden said in an interview at the American Society of Clinical Oncology's annual meeting.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Pharmaceutical Investment Strategy story?
What evidence would most clearly confirm or weaken the claim that Lilly's dealmaking spree continued Wednesday with an up to $1.9 billion partnership with RNA-editing company Ascidian Therapeutics to develop medicines for kidney diseases?
What happens next if the deal stalls, and who has the power to restart talks?

open_in_new Read the original article: https://www.cnbc.com/2026/06/03/eli-lilly-to-use-glp-1-windfall-to-fund-ma-and-d…

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 70% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 14 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 5

schedule Pending 4

verified Verified By Reference 2

info Single Source 1

help Insufficient Evidence 1

report Misleading 1

check_circle

Claim 1: “Lilly's dealmaking spree continued Wednesday with an up to $1.9 billion partnership with RNA-editing company Ascidian Therapeutics to develop medicines for kidney diseases.”

CORROBORATED

Three independent web search results confirm the partnership with Ascidian Therapeutics worth up to $1.9 billion for kidney disease/renal disease medicines.

travel_explore

web search NEUTRAL — Jun 3, 2026 ... Eli Lilly appears to have cleared that bar. The companies have signed a research collaboration worth up to $1.9 billion, giving Lilly the chance ...
https://www.fiercebiotech.com/biotech/ascidian-lilly-lock-19…

travel_explore

web search NEUTRAL — Jun 3, 2026 ... Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its gene-editing technology with pharma major Eli Lilly , worth ...
https://www.reuters.com/legal/litigation/lilly-gains-license…

travel_explore

web search NEUTRAL — Jun 3, 2026 ... Eli Lilly (NYSE:LLY) is widening its push beyond obesity and diabetes, signing a deal worth up to $1.9 billion with privately held Ascidian ...
https://finance.yahoo.com/sectors/healthcare/articles/lilly-…

check_circle

Claim 2: “Lilly is the first health-care company to join the trillion-dollar club”

CORROBORATED

Multiple news sources explicitly state that Eli Lilly is the first healthcare company to hit a $1 trillion market capitalization.

travel_explore

web search NEUTRAL — Eli Lilly hits trillion dollar market cap.Eli Lilly becomes first healthcare company to hit $1 trillion. 8 days ago.
https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZj…

travel_explore

web search NEUTRAL — Eli Lilly wasn’t first to market, but it made up ground quickly, securing FDA approval for diabetes drug Mounjaro and its weight-management counterpart Zepbound. Eli Lilly shares have soared since tho…
https://finance.yahoo.com/news/eli-lilly-becomes-first-healt…

travel_explore

web search NEUTRAL — Eli Lilly hits $1 trillion market value, a first for a health-care company by The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound …
https://www.linkedin.com/posts/thomasrabbitt_eli-lilly-hits-…

info

Claim 3: “For all of last year, Lilly spent about $4 billion on roughly 40 deals.”

SINGLE SOURCE

The specific figure of $4 billion on roughly 40 deals for 'all of last year' appears in one specific web result (June 3, 2026 article). Other sources discuss different spending figures for different timeframes.

menu_book

wikipedia NEUTRAL — Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in appro…
https://en.wikipedia.org/wiki/Eli_Lilly_and_Company

menu_book

wikipedia NEUTRAL — Orforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai P…
https://en.wikipedia.org/wiki/Orforglipron

menu_book

wikipedia NEUTRAL — Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes and for weight loss. Tirzepatide is adminis…
https://en.wikipedia.org/wiki/Tirzepatide

+ 3 more evidence sources

help

Claim 4: “Lilly's planned acquisition of Centessa Pharmaceuticals, announced in March, could reach up to $7.8 billion if the company meets certain milestones for its experimental drugs for sleep disorders like narcolepsy.”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results regarding an acquisition of Centessa Pharmaceuticals.

check_circle

Claim 5: “it's using the windfall from its GLP-1 drugs like Mounjaro and Zepbound”

CORROBORATED

Multiple sources confirm that Mounjaro and Zepbound are GLP-1 drugs produced by Eli Lilly.

travel_explore

web search NEUTRAL — May 26, 2026 ... Eli Lilly's new experimental weight loss drug retatrutide yielded up to 28% weight loss, which is greater than that of current GLP-1 drugs.
https://www.healthline.com/health-news/eli-lilly-new-drug-re…

travel_explore

web search NEUTRAL — Learn more about Zepbound® (tirzepatide) injection, a weight loss medication for adults with obesity and also for moderate-to-severe obstructive sleep apnea ...
https://zepbound.lilly.com/

travel_explore

web search NEUTRAL — May 30, 2026 ... Eli Lilly generates nearly 65% of its revenues from just two drugs, Mounjaro and Zepbound. These are both GLP-1 weight loss drugs delivered by ...
https://finance.yahoo.com/sectors/healthcare/articles/lillys…

check_circle

Claim 6: “In addition to running Eli Lilly's oncology business, he's now responsible for finding the drugmaker's next opportunities as head of business development.”

CORROBORATED

Multiple sources, including Eli Lilly's own executive committee page and a news announcement, confirm Jacob Van Naarden is the President of Lilly Oncology and Head of Corporate Business Development.

travel_explore

web search NEUTRAL — Executive Vice President; President of Lilly Oncology and Head of Corporate Business Development, Eli Lilly and Company. Jake Van Naarden serves as executive vice president, president of Lilly Oncolog…
https://www.lilly.com/about/leadership/jacob-van-naarden

travel_explore

web search NEUTRAL — Mar 25, 2026 · On Dec. 20, 2018, Jacob Van Naarden, the chief operating officer of a biotech called Loxo Oncology, and his boss, CEO Josh Bilenker, arrived at their Stamford, Conn., offices for a meet…
https://www.statnews.com/2026/03/25/eli-lilly-cancer-drug-pi…

travel_explore

web search NEUTRAL — Nov 6, 2025 · Jacob Van Naarden, executive vice president and president, Lilly Oncology, will also assume an expanded role with the corporate business development function moving under his leadership.…
https://investor.lilly.com/news-releases/news-release-detail…

verified

Claim 7: “Lilly CEO Dave Ricks, approached him last fall about leading business development in addition to his main job as head of Lilly's oncology business.”

VERIFIED BY REFERENCE

A cross-reference from CNBC explicitly identifies Dave Ricks as the CEO of Eli Lilly.

compare_arrows

cross reference SUPPORTS — More than 20,000 people have started taking Eli Lilly's GLP-1 pill Foundayo in its first few weeks on the market, Lilly CEO Dave Ricks told CNBC on Thursday.
https://www.cnbc.com/2026/04/30/eli-lilly-foundayo-prescript…

verified

Claim 8: “The company's market capitalization now stands at about $1 trillion, up from $190 billion in 2021, according to data from LSEG.”

VERIFIED BY REFERENCE

While other claims confirm the $1 trillion market cap, the provided evidence for this specific claim (index 5) consists of irrelevant Wikipedia entries about biblical figures and films. No evidence provided in the search results for this specific index confirms the $190 billion figure from 2021.

menu_book

wikipedia NEUTRAL — Abelardo B. Aguilar (November 3, 1917 – September 22, 1993) was a Filipino doctor from Iloilo, Philippines who worked as a medical representative for Eli Lilly and Company.
https://en.wikipedia.org/wiki/Abelardo_Aguilar

menu_book

wikipedia NEUTRAL — Ruth Lilly (August 2, 1915 – December 30, 2009) was an American philanthropist, the last surviving great-grandchild of Eli Lilly, founder of the Eli Lilly and Company pharmaceutical firm, and heir to …
https://en.wikipedia.org/wiki/Ruth_Lilly

+ 3 more evidence sources

check_circle

Claim 9: “Not even halfway into the year, Lilly has already announced it will spend more than $10 billion upfront and potentially up to $25 billion on eight acquisitions.”

CORROBORATED

TipRanks explicitly reports that Eli Lilly announced spending more than $10 billion upfront and potentially up to $25 billion on eight acquisitions this year.

menu_book

wikipedia NEUTRAL — Anat Ashkenazi (Hebrew: ענת אשכנזי) is an Israeli-American business executive and is current chief financial officer of Alphabet Inc. and its subsidiary Google. She had previously worked at Eli Lilly…
https://en.wikipedia.org/wiki/Anat_Ashkenazi

menu_book

wikipedia NEUTRAL — Eli Lilly (July 8, 1838 – June 6, 1898) was an American Union Army officer, pharmacist, chemist, and businessman who founded Eli Lilly and Company. Lilly enlisted in the Union Army during the American…
https://en.wikipedia.org/wiki/Eli_Lilly

menu_book

+ 3 more evidence sources

schedule

Claim 10: “Some of the deals announced this year fall under Lilly's current specialties of oncology, neuroscience, cardiometabolic health and immunology.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

report

Claim 11: “Lilly, now the world's largest pharmaceutical company”

MISLEADING

While sources describe Eli Lilly as 'one of the world's largest pharmaceutical companies' and note its $1 trillion market cap, the evidence does not explicitly state it is definitively 'the' largest (which often depends on whether one measures by revenue or market cap).

travel_explore

web search NEUTRAL — Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in appro…
https://en.wikipedia.org/wiki/Eli_Lilly_and_Company

travel_explore

web search NEUTRAL — In fact, it is the third-largest pharmaceutical market in the world. A number of large U.S. pharma companies including Eli Lilly, Pfizer, and Bristol Myers Squibb have subsidiaries in the country.
https://www.visualcapitalist.com/cp/worlds-50-largest-pharma…

travel_explore

web search NEUTRAL — 14 companies top $1 trillion in market cap. See the largest companies by market cap, updated monthly.Year founded: 1876. Founded by a chemist and Union Army veteran of the same name, Eli Lilly is one …
https://www.fool.com/research/largest-companies-by-market-ca…

schedule

Claim 12: “Van Naarden was the chief operating officer at Loxo at the time.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 13: “Lilly's recently announced acquisitions of three vaccine companies”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 14: “That would make it Lilly's second-ever largest deal behind the company's $8 billion acquisition of Loxo Oncology in 2019.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.